---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006005"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T13:00:13.527655+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences raises ~$6M in private placement at $9.00/share

## Summary
- Sold 666,334 shares (or pre-funded warrants) at $9.00 each, plus Series A and B investment options for up to 666,334 shares each at $9.00.
- Existing warrants with exercise prices from $37 to $301 amended to $9.00 per share, contingent on closing.
- H.C. Wainwright acted as placement agent with 6% fee and 5% placement agent investment options at $11.25.
- Closing expected March 6, 2023; registration rights agreement requires filing by April 3, 2023.
- Proceeds not explicitly stated but gross from shares alone approximately $6 million.

## SEC filing metadata
- accession: 0000950170-23-006005
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017023006005/0000950170-23-006005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017023006005/rkda-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006005
- JSON: https://secwatch.observer/filing/0000950170-23-006005.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006005.txt

## Key facts
- Material Agreements
  Arcadia Biosciences, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2023-03-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Effective: 2023-03-02
  source text: Also on March 2, 2023 and in connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023006005/0000950170-23-006005-index.htm
- Material Agreements
  Arcadia Biosciences, Inc. amended Option Amendment Agreements with the Purchasers (effective 2023-03-02).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Effective: 2023-03-02
  source text: Concurrent with the Private Placement, the Company entered into preferred investment option amendment agreements (the “Option Amendment Agreements”) with the Purchasers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023006005/0000950170-23-006005-index.htm
- Material Agreements
  Arcadia Biosciences, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-03-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2023-03-02
  source text: The Company entered into an engagement letter with H.C. Wainwright & Co., LLC (“Wainwright”) dated March 2, 2023 (the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the Company’s exclusive placement agent for certain equity financing transactions, including the Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023006005/0000950170-23-006005-index.htm
- Material Agreements
  Arcadia Biosciences, Inc. entered into Purchase Agreement with certain institutional and accredited investors (effective 2023-03-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Effective: 2023-03-02
  source text: On March 2, 2023, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023006005/0000950170-23-006005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.